Novartis

Therapeutic Area Head Oncology

INSURGENTES Full time

Job Description Summary

LI-Hybrid

Location: CDMX, Mexico

Step into a pivotal leadership role where your vision will shape the future of oncology in Mexico. As TA Head Oncology, you’ll drive strategic launches of breakthrough oncology therapies, lead the largest Novartis Mexico team, and navigate a dynamic healthcare landscape with agility and innovation. This is your opportunity to make a lasting impact on patients’ lives while building a high-performing, purpose-driven organization. If you're ready to lead with heart, inspire change, and deliver results, we want to hear from you.


 

Job Description

Essential Requirements

  • Bachelor’s Degree
  • Proven track record of inspirational leadership in complex healthcare environments
  • Deep understanding of Mexico’s healthcare system and regulatory landscape
  • Over 10 years of experience in the pharmaceutical or healthcare industry
  • Demonstrated success in launching and pre-launching oncology therapies
  • Experience leading large, cross-functional sales and marketing teams
  • Strong stakeholder engagement and access strategy expertise
  • High agility and resilience in navigating change and ambiguity
  • Ability to foster a culture of growth, ethics, and enterprise mindset

Desirable Requirements

  • Experience across multiple oncology business units or therapeutic areas.
  • Exposure to regional or global strategic roles within the pharmaceutical industry.


 

Skills Desired

Agility, Agility, Asset Management, Business Development, Business Strategy, Commercial Excellence, Cross-Functional Collaboration, Customer Orientation, Digital Marketing, Go-To-Market Strategy, Healthcare Sector Understanding, Influencing Skills, Inspirational Leadership, Key Account Management, Market Access, Marketing Strategy, Market Share, Market Trends, Negotiation Skills, People Management, Priority Disease Areas Expertise, Product Launches, Product Lifecycle Management (PLM), Product Positioning, Profit and Loss (P&L) {+ 5 more}